Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
82 hedge funds and large institutions have $79.7M invested in Adverum Biotechnologies in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 11 closing their positions.
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
25% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 20
8% more funds holding
Funds holding: 76 → 82 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
48% less capital invested
Capital invested by funds: $153M → $79.7M (-$73.2M)
71% less call options, than puts
Call options by funds: $343K | Put options by funds: $1.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.23M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.93M |
| 3 |
Renaissance Technologies
New York
|
+$1.1M |
| 4 |
JAM
JW Asset Management
Miami Beach,
Florida
|
+$1.06M |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$523K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
-$7.9M |
| 2 |
Axa
Paris,
France
|
-$6.59M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.14M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.47M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$1.18M |
ADVM Hedge Fund Activity: Q1 2016 in Review
82 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q1 2016, worth a combined $79.7M — down 48% from $153M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ADVM positions and 11 closed out — a net gain of 6 holders — while 25 added to existing stakes and 20 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $7.23M. The largest seller was Cadian Capital Management, cutting an estimated $7.9M.
- 82 institutional investors held Adverum Biotechnologies (ADVM) as of Q1 2016, up from 76 in Q4 2015.
- Funds reported $79.7M of Adverum Biotechnologies stock for Q1 2016, down 48% quarter-over-quarter.
- 17 funds opened new Adverum Biotechnologies positions in Q1 2016 and 11 closed out, a net change of +6 holders.
- The largest Adverum Biotechnologies buyer in Q1 2016 was Great Point Partners, an estimated $7.23M added.
- The largest Adverum Biotechnologies seller in Q1 2016 was Cadian Capital Management, an estimated $7.9M sold.
Based on aggregated 13F filings for Q1 2016.